Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas. The effect of vessel dilator, kaliuretic peptide and cyclic GMP on MEK 1/2 kinase were examined in human prostate adenocarcinoma cells. Vessel dilator and kaliuretic peptide decreased the activation of MEK 1/2 over a concentration range of 0.01 microM to 10 microM. Vessel dilator and kaliuretic peptide (each 10 microM) inhibited the phosphorylation of MEK 1/2 kinase by 98% (p < 0.0001) and 81% (p < 0.001), respectively. The inhibition of MEK 1/2 lasted for at least two hours, where it was maximal, secondary to both peptides. Their ability to inhibit MEK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited MEK 1/2 phosphorylation. Vessel dilator and kaliuretic peptide both inhibit MEK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.